Ozempic is available but is not licensed for weight management but only treatment of diabetes
For states of systemic inflammation that involve cells of the peripheral immune system, while for neurodegenerative and neuroinflammatory diseases such as AD, PD, and MS, penetration of the CNS is necessary (Salem et al., 2015) (Figure 4)
This dual mechanism (direct scavenging plus activation of endogenous defenses) addresses limitations of conventional antioxidants that work through single pathways
Insulin, androgens, and estrogens tend to enhance IGF-1 secretion, whereas glucocorticoids inhibit it
Other GLP-1 Medications Although Ozempic (semaglutide) is a member of the GLP-1 class, its formulation distinguishes it from other medications such as Mounjaro (tripeptidea dual GLP-1 and GIP agonist) and Wegovy (also semaglutide, but at a larger dose) by enabling: Once-weekly dosing Sustained effects on appetite Strong glucose control This makes it suitable for long-term chronic management
For patients seeking support with medical weight loss, GLP-1 receptor agonists such as Ozempic (semaglutide GLP-1) can be an effective tool when used as part of a comprehensive, physician-guided plan